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Bonsignore MR, Morici G, Riccioni R, Huertas A, Petrucci
E, Veca M, Mariani G, Bonanno A, Chimenti L, Gioia M,
Palange P, Testa U. Hemopoietic and angiogenetic progenitors in
healthy athletes: different responses to endurance and maximal
exercise. J Appl Physiol 109: 60 – 67, 2010. First published May 6,
2010; doi:10.1152/japplphysiol.01344.2009.—The effects of endur-
ance or maximal exercise on mobilization of bone marrow-derived
hemopoietic and angiogenetic progenitors in healthy subjects are
poorly defined. In 10 healthy amateur runners, we collected venous
blood before, at the end of, and the day after a marathon race (n  9),
and before and at the end of a 1.5-km field test (n  8), and measured
hemopoietic and angiogenetic progenitors by flow cytometry and
culture assays, as well as plasma or serum concentrations of several
cytokines/growth factors. After the marathon, CD34 cells were
unchanged, whereas clonogenetic assays showed decreased number of
colonies for both erythropoietic (BFU-E) and granulocyte-monocyte
(CFU-GM) series, returning to baseline the morning post-race. Con-
versely, CD34 cells, BFU-E, and CFU-GM increased after the field
test. Angiogenetic progenitors, assessed as CD34KDR and
CD133VE-cadherin cells or as adherent cells in culture expressing
endothelial markers, increased after both endurance and maximal
exercise but showed a different pattern between protocols. Interleu-
kin-6 increased more after the marathon than after the field test,
whereas hepatocyte growth factor and stem cell factor increased
similarly in both protocols. Plasma levels of angiopoietin (Ang) 1 and
2 increased after both types of exercise, whereas the Ang-1-to-Ang-2
ratio or vascular endothelial growth factor-A were little affected.
These data suggest that circulating hemopoietic progenitors may be
utilized in peripheral tissues during prolonged endurance exercise.
Endothelial progenitor mobilization after exercise in healthy trained
subjects appears modulated by the type of exercise. Exercise-induced
increase in growth factors suggests a physiological trophic effect of
exercise on the bone marrow.
angiopoietin; marathon; circulating progenitors; growth factors
RELEASE OF BONE MARROW-DERIVED progenitors (CD34 cells)
occurs after acute exercise (18, 21, 22, 28, 39, 40) and might be
involved in repair processes, i.e., at the level of skeletal
muscle, as suggested by some experimental studies (16, 25). In
recent years, endothelial progenitor cells (EPCs) have been
extensively investigated because of their angiogenetic activity
and potential usefulness in the clinical setting (26, 32). Partic-
ularly, recent studies in animals and humans unveiled the
ability of EPCs to ameliorate the function of ischemic organs
possibly by both induction and mobilization of angiogenesis
(incorporation into damaged vessels and paracrine action) and
to support re-endothelization of injured arteries by replacing
the dysfunctional endothelial cells (9, 37).
Several EPC markers have been identified (31, 33, 41), and
CD34KDR cells, CD34CD133 cells, CD133VE-cad-
herin cells, or monocyte/macrophage-derived angiogenic
cells (CACs) have been shown to increase after acute exercise
(18, 27, 28, 40). As for the effects of chronic exercise, circu-
lating EPCs increased after training in healthy subjects (17)
and children (42), whereas no major change in progenitor
release was reported in healthy young or older men in relation
to training status (39).
EPCs could be involved in training-induced capillarization
of skeletal muscle, but the mechanism(s) of their mobilization
from bone marrow are still incompletely understood. Hypoxia
may play a role, as suggested by the high plasma concentra-
tions of vascular endothelial growth factor (VEGF) A found in
animal models and patients with ischemic cardiovascular dis-
ease (1, 17, 30, 34). However, unchanged (28, 39) or increased
(8, 21) plasma VEGF-A levels were found after exercise in
normal subjects. In addition, little is known on the possible role
of other angiogenetic factors, such as hepatocyte growth factor
(HGF) (4), or angiopoietin (Ang) 1 and 2 in the mobilization of
progenitors induced by exercise. Finally, exercise may cause
release of VEGF-C or VEGF-D, which are believed to be
involved in lymphangiogenesis (12, 29).
Athletes are the ideal population to assess the physiological
effects of intense exercise and training. In our first study, flow
cytometry in whole blood showed increased circulating
CD34 cells at rest in well trained runners compared with
sedentary controls (3). CD34 cells were unchanged immedi-
ately after a marathon or half-marathon race but decreased on
the day post-race (3). In advanced-age marathon runners,
Adams and coworkers recently reported that hemopoietic pro-
genitors decreased at the end of the marathon race, whereas the
proportion of CD34KDR cells out of the total CD34 cells
increased (2). Increased EPCs were reported up to 48 h pos-
texercise in competitive runners after a 246-km race (10).
Finally, in young competitive rowers, we showed release of
bone marrow-derived progenitors after supramaximal exercise
(“all-out” rowing) (22).
The pattern of circulating cytokines/growth factors possibly
involved in progenitor release differed after prolonged aerobic
exercise (marathon or half-marathon) and all-out rowing (3,
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22), suggesting that exercise intensity and/or duration may
modulate progenitor release; alternatively, the response to
exercise may vary according to the type of training.
The present study was designed with two aims. The first aim
was to further characterize the release and mobilization of bone
marrow-derived progenitors, including angiogenetic ones, in
amateur runners at rest, at the end of a marathon race, and
the following morning. Different subpopulations of EPCs
[CD34KDR cells, CD133VEcadherin cells, and mono-
cyte-derived circulating angiogenetic cells (CACs)] were as-
sessed, together with a panel of angiogenetic mediators/growth
factors [HGF, VEGF-A, -C, and -D, stem cell factor (SCF),
interleukin (IL)-6]. The second aim was to compare the effects
of a marathon race to those of a maximal test in the same
runners, studied at rest and after 1.5 km of running, to further
characterize progenitor release in response to endurance and
maximal exercise.
METHODS
Ten healthy male amateur runners were studied. Nine subjects
participated in the marathon protocol (age: 43.6  11.6 yr; training
volume: 88  35 km/wk; race experience: 9.3  6.5 yr; range: 1–20
yr), whereas eight subjects underwent the 1,500-m field test protocol
(age: 43.4  10.9 yr; training volume: 90  38 km/wk). The two
groups did not differ significantly for age or training volume. Seven
subjects participated in both protocols. The study was approved by the
local Ethical Committee, and written, informed consent was obtained
from all subjects.
Marathon and field test. The Palermo International Marathon was
held on November 20, 2005. Average race time of the group was
191  26 min. The field tests were obtained on May 10, 2006 on a
400-m track. In the field test, subjects ran 1,500 m at their maximum
speed after mild warm-up for 20 min at 75% of their maximal
predicted heart rate (130 beats/min). Oxygen consumption was
measured during the field tests (COSMED K4b), and averaged 45 
6 ml ·min1 ·kg1 in the last minute of exercise. Subjects covered the
1,500 m distance in 5 min 35 s  35 s and attained a maximal heart
rate of 178 6 beats/min (101 5% of their maximal predicted heart
rate) during the test.
Venous blood sample collection and processing. Venous blood was
collected in EDTA for standard blood cell and reticulocyte counts, and
in heparinized tubes for analysis of progenitors. Aliquots of plasma
and serum were prepared and stored at 80°C until analysis. Similar
to our laboratory’s previous study (3), blood samples were obtained in
the marathon protocol 1) at rest in the morning 2 or 3 days before the
race, 2) at the end of the race (on average 8 2 min after arrival), and
3) at rest in the morning 18–20 h after end of the race. For the
field-test protocol, blood samples were obtained on the same day, at
rest before the 20-min warm-up and at 3–5 min after the end of the
test, respectively. Venous blood was kept at 4°C until analysis for
total blood cell counts (ADVIA) and progenitors (see below).
Peripheral blood mononuclear cells isolation. Peripheral blood
mononuclear cells (PBMCs) were obtained by standard Ficoll gradi-
ent centrifugation. Briefly, heparin-anticoagulated blood was diluted
1:1 with Iscove’s Modified Dulbecco’s Medium (IMDM, GIBCO),
slowly pipetted on a cushion of Ficoll-Hypaque separation medium,
and then centrifuged for 20 min at 400 g and 20°C. At the end of the
centrifugation, floating cells were recovered, washed three times with
PBS, resuspended in IMDM medium, counted, and then used for
various assays. Cell viability was used for various assays. Cell
viability was assessed using the vital trypan blue supravital staining.
Flow cytometry characterization of circulating mononuclear cells.
Cells were carefully washed with PBS, resuspended in PBS contain-
ing 2 mg/ml bovine serum albumin, and labeled for 30 min at 4°C
with the antibody phycoerythrin (PE)-conjugated anti-CD34 (Becton
Dickinson-Pharmingen, Lincoln Park, NJ) or with PE-conjugated
anti-CD133 monoclonal antibodies (Miltenyi Biotech, Bergisch Glad-
bach, Germany).
Circulating endothelial progenitors are thought to express CD34
and endothelial markers such as CD144 (VE-Cadherin) and KDR
(VEGF-R2). These progenitors were evaluated by independent oper-
ators, blind to the data, by flow cytometry with CD34/KDR, CD34/
VE-Cadherin (CD144), and CD133/VE-Cadherin double labeling.
These CD34/KDR and CD133/VE-Cadherin cells are cell populations
enriched for EPCs, and their measure can be considered an indicator
of the number of circulating EPCs. Briefly, for the latter, aliquots of
1  106 PBMC were incubated for 45 min on ice with antibodies
against human CD34 (FITC-conjugated, BD Biosciences) or against
human CD133 (FITC-conjugated, Miltenyi) and either KDR or
VE-Cadherin (PE-conjugated, R&D Systems). Respective isotype-
matched FITC- or PE-conjugated antibodies from the same manufac-
turers served as controls. Incubation was followed by three PBS
washings. Flow cytometry measurement was performed using appro-
priate fluorescence compensation and light scatter gating, excluding
dead cells, in a FACS SCAN Cytometer (Becton Dickinson). At least
400,000 events were measured within the lymphocyte gate. Analysis
was performed using the fluorescence-1/fluorescence-2 dot plot quad-
rant statistics and manual gating (Cell Quest Pro Software, Becton
Dickinson). In our laboratory, the intra-assay coefficient of variation
was 6% for total CD34 and CD133 evaluation, 15.5% for CD34/
KDR, and 16.8% for CD133/VE-Cadherin cells.
The calculation of total cell numbers of CD34 or CD133 and their
subpopulations was obtained by multiplying the percentage of these cells
(measured by FACS analysis on a lymphocyte gate) for total lymphocyte
cell count.
Natural killer cell evaluation. To determine the number of natural
killer (NK) cells, PBMC were labeled with a PE-conjugated anti-
human CD56 mAb (Becton Dickinson), the lymphocyte cell popula-
tion was gated, and the percentage of CD56 cells (dim and bright)
cells was determined. The number of NK (CD56) lymphocytes per
milliliter of blood was obtained by multiplying the percentage of
CD56 cells for the total lymphocyte cell number.
Colony forming assays. For the colony forming unit (CFU) assay,
PBMCs were seeded at 3  105 cells ·ml1 ·dish1 (Falcon 1008;
Becton Dickinson) in 0.9% methylcellulose and 40% fetal calf serum
(GIBCO, Grand Island, NY) in Iscove’s modified Dulbecco’s medium
(GIBCO), which was supplemented with 1.5 IU/ml erythropoietin for
erythrocyte burst-forming units (E-BFU) colonies, 10 ng/ml of both
granulocyte-monocyte colony stimulating factor (GM-CSF), and
G-CSF for granulocyte-monocyte colony-forming units (GM-CFU).
For CFU-GEMM colonies assay (Colony Forming Units-Granulo-
cyte, Erythrocyte, Monocyte, Megakaryocyte), all the growth factors
used for BFU-E and CFU-GM colony assays were added together.
Colonies were counted under an inverted microscope after 14–16
days of culture. Data are expressed as the number of colonies per
milliliter of blood.
Monocyte-derived angiogenic cells (CACs): isolation and
characterization. Monocyte-derived angiogenic cells were obtained by
in vitro growth of PBMCs using a procedure previously reported by
Kalka et al. (13). After resuspension in endothelial basal medium
(EBM-2; Clonetics) supplemented with EGM-2-MV-SingleQuots
(Clonetics) containing VEGF, basic fibroblast growth factor, insulin-
like growth factor-1, epidermal growth factor, and 10% FBS, 1  106
cells/cm2 were plated on fibronectin-coated tissue culture dishes.
After 4 days of culture, nonadherent cells were discarded by washing
with PBS, and adherent cells were cultured in the same endothelial
culture medium usually for 7–10 days and up to 3 wk. To confirm the
EPC phenotype, adherent cells were incubated with Dil-labeled
acLDL (Molecular Probes) for 1 h, and after fixation were incubated
with FITC-labeled Ulex europaeus agglutinin 1 for 1 h. Cells were
visualized with an inverted microscope equipped for fluorescence, and
adherent cells staining positive for both markers were judged to be
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monocytic angiogenetic cells. These cells were characterized also for
the expression of membrane endothelial markers [i.e., VE-Cadherin
(CD144), KDR (VEGF-R2), Tie-2, CD31, CD151, CD34]. The
monocytic origin of these cells was confirmed by the positivity for
CD14 antigen expression.
Evaluation of growth factor and cytokine concentrations. Aliquots
of plasma and serum were prepared and stored at 80°C for deter-
mination by immunoassay (ELISA, R&D Systems, Minneapolis, MN)
of the following pro-angiogenetic factors, as previously described
(11): 1) VEGF-A, as a marker of tissue hypoxia and angiogenesis
(detection limit: 0.5 pg/ml); 2) VEGF-C and VEGF-D, known to
induce mitogenesis, migration and survival of endothelial cells, and
lymphoangiogenesis (detection limit: 5 pg/ml); 3) HGF, a mediator
known to activate proliferation and migration of endothelial cells and
induce angiogenesis (detection limit: 20 pg/ml); 4) SCF acting on
early hemopoiesis (detection limit: 5.0 pg/ml); 5) Ang-1 known to
strongly promote angiogenesis through the Tie-2 receptor pathway
(detection limit: 10 pg/ml); and 6) Ang-2 known to be involved in the
induction of inflammation (detection limit: 10 pg/ml). IL-6 was
assessed by immunoassay (ELISA, detection limit: 0.16 pg/ml, R&D
Systems).
Muscle enzymes (lactic dehydrogenase or LDH and creatine kinase
or CK) were measured by enzymatic assays (Olympus 640 kits and
equipment, Olympus Diagnostica, Hamburg, Germany) only in the
marathon protocol, since they were previously found to be unchanged
after short-lived exercise (22).
Statistics. Data are reported as means  SD or median (interquar-
tile range). Analysis was performed by a statistical software (Statview
5.01, SAS Institute, Cary, NC). ANOVA with Bonferroni correction
(or Kruskal-Wallis test for non-normally distributed variables) were
used to compare results at different time points in the marathon
protocol. Paired t-test was used to assess exercise-induced changes
from baseline in the field test protocol. Unpaired t-test was used to
compare baseline values from both protocols and exercise-induced
changes in angiogenetic progenitors and growth factors between
protocols. Linear regression was used to assess correlations between
variables. Significance was at P  0.05 for all tests.
RESULTS
Blood cell counts. Table 1 reports the main data on blood
cell counts in both protocols (marathon and 1,500-m field test).
A marked rise in white blood cell counts associated with a
moderate rise in platelet counts was observed at the end of the
marathon race, returning toward baseline values the morning
post-race (Table 1). White blood cell counts also increased after
the field test but to a lesser extent compared with the marat-
hon race. Intense neutrophilia was observed only after the
marathon race. After the field test, lymphocyte counts and the
natural killer subpopulation (CD56) increased significantly.
Changes of CD34 and CD133 cells. The number of total
CD34 cells, as evaluated by flow cytometry, was virtually
unaffected by the marathon race (pre-race: 6,800 932; end of
race: 4,550  727 cells/ml of blood; post-race: 5,810  741
cells/ml of blood; P  not significant by ANOVA) (Fig. 1).
Conversely, analysis of hemopoietic progenitor cells using a
standard clonogenetic assay showed a significant decline in the
number of colonies at the end of the race returning to baseline
values the following morning (Fig. 1; BFU-E: P  0.01,
post-race vs. end of race; CFU-GM: P  0.005 pre- and
Table 1. Blood cell counts
Marathon Field Test
Pre-Race End Race Post-Race Pre-Race End Race
RBC, ·106/l 4.71  0.30 4.80 0.29 4.56 0.35 4.72 0.34 5.00 0.30
Hct, % 41.1  1.8 42.6 1.9 40.7 2.9 39.4 1.8 42.6 1.2*
Platelets, · 103/l 204  27 311 62† 214 45 241 50 272 44
WBC, ·103/l 6.74  2.17 17.33 3.71† 7.48 1.62 6.76 1.89 10.91 3.18*
Neutrophils, · 103/l 3.63  1.11 14.45 3.12† 4.71 2.01 3.71 1.04 5.61 2.53
Lymphocytes, · 103/l 2.24  0.90 1.86 0.65 2.01 0.73 2.28 0.81 4.15 0.92*
Monocytes, · 103/l 0.45  0.27 0.79 0.26† 0.42 0.16 0.35 0.16 0.52 0.09
NK, lymphocytes/l 332  226 226 140 326 215 309 235 729 456*
Values are means  SE. RBC, red blood cell; Hct, hematocrit; WBC, white blood cell; NK, natural killer. Significant difference (P  0.05): *vs. baseline;
†vs. baseline and post-race.
Fig. 1. Effects of a marathon race and of 1.5-km field test on circulating
hemopoietic progenitors. Top left: CD34 cells. Top right: CD133 cells.
Middle left: burst forming unit for erythrocytes (BFU-E). Middle right:
granulocyte-monocyte colony forming units (CFU-GM). Bottom: granulocyte,
erythrocyte, monocyte, and megacariocyte colony forming units (GEMM-
CFU). See text for methodological details. Significant difference (P  0.05):
*vs. rest; §vs. race; #vs. rest and post-race.
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post-race vs. end of race; CFU-GEMM: P 0.05, post-race vs.
end of race).
After the field test, both the number of circulating CD34 cells
and the number of progenitors assessed by colony assays in-
creased significantly (Fig. 1; CD34 cells: P  0.005; BFU-E:
P  0.0001; CFU-GM: P  0.0001; CFU-GEMM: P  0.005).
CD133 cells showed a pattern of release similar to that
observed for CD34 cells (Fig. 1), i.e, no changes during or
after the marathon race (P  not significant) and increase after
the field test (P  0.001).
Endothelial progenitors. Two subpopulations of endothelial
progenitors were evaluated by flow cytometry: 1) endothelial
progenitor cells (EPCs) that co-express stem cell/progenitor
cell markers, such as CD34 or CD133, and endothelial mark-
ers, such as KDR or VE-Cadherin; 2) monocyte-derived endo-
thelial cells, known as circulating angiogenic cells (CAC).
For the evaluation of EPCs, aliquots of 1  106 PBMCs
were incubated with anti-KDR-PE and anti-CD34-FITC or
anti-VE-Cadherin-PE and anti-CD34-FITC. The number of CD34/
KDR or CD34/VE-Cadherin cells was analyzed in the small
lymphocyte region (see a representative analysis in Fig. 2). The
number of CD133VE-Cadherin or CD34KDR cells as-
sessed by flow cytometric analysis showed a nearly twofold
increase in peripheral blood at the end of the marathon race
(CD133VE-Cadherin cells: P  0.05, end of race vs. pre-race;
CD34KDR cells: P  0.005, end of race vs. pre- and post-race)
and returning to baseline values the following morning (Fig. 3, A and
B). The exercise-induced increase in the number of
CD133Ve-Cadherin and CD34KDR cells was more pro-
nounced (nearly threefold) after the field test (Fig. 3, A and B;
CD133VE-Cadherin cells: P  0.01; CD34KDR cells:
P  0.01). In contrast, cells positive for CD133 but negative
for VE-Cadherin (AC133VE-Cadherin), mainly represent-
ing hemopoietic progenitors and immature hemopoietic pre-
cursors, showed a moderate decrease at the end of race (data
not shown).
Analysis of CACs showed a marked increase from baseline
values (8,489 1,850 cells/1 106 PBMCs) to post-marathon
values (30,210  4,560/1  106 PBMCs), returning almost to
baseline (10,861  1,818 cells/1  106 PBMCs) the morning
post-race (ANOVA: P  0.0001, end of race vs. pre- and
post-race; Fig. 3C). CACs also increased after the field test,
although to a lesser extent (P  0.005). Figure 3D summarizes
the effects of the two exercise protocols on angiogenetic
progenitor subpopulations. KDR cells increased similarly in
the two protocols. Conversely, CD133VE-cadherin cells
increased especially after the field test (P  0.01), whereas
CAC increased preferentially after the marathon race (P 
0.01).
Growth factors and mediators. Table 2 summarizes the
results of the measurements in serum/plasma in the marathon
and field test protocols. Similar to our previous study (3), IL-6
increased after both exercise protocols (marathon: ANOVA
P 0.0001; field test: P 0.05), but the increase after the marathon
race was much larger than after the field test. HGF (marathon:
ANOVA P  0.0001; field test: P  0.01) and SCF levels
(marathon: ANOVA P  0.01; field test: P  0.05) increased
similarly after both protocols. VEGF-A and VEGF-D levels were
not significantly affected by either type of exercise, and the
former showed a tendency to decrease after the marathon.
Fig. 2. Flow cytometry analysis of endothelial progenitor cells (EPCs) in peripheral blood (PB) in one subject at baseline (top) and after the 1.5-km field test
(bottom). Mononuclear cells isolated from PB were gated in a forward-scatter (FSC)/side-scatter (SSC) plot (left): the cell population corresponding to small
lymphocytes was gated and analyzed for background fluorescence after labeling with isotype-matched control mouse IgGs (second panel from left), for CD34
and KDR cells after labeling with anti-CD34 and anti-KDR mAbs (third panels from left), or for CD133 and VE-Cadherin cells after labeling with
anti-CD133 and anti-VE-Cadherin mAbs (right).
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VEGF-C increased the day after the marathon race, whereas its
change immediately post-race did not reach statistical signifi-
cance (marathon: ANOVA P  0.05); a small but significant
increase in VEGF-C level was observed at the end of the field
test (P  0.001). Ang-1 increased significantly after exercise
only in the marathon protocol, with a similar trend after the field
test (marathon: ANOVA P  0.01; field test: P  0.06; Fig. 4).
Ang-2 increased significantly after exercise in both tests (mara-
thon: ANOVA P 0.001; field test: P 0.005, Fig. 4), whereas
the ratio of Ang-1 to Ang-2 was unaffected by either type of
exercise (Fig. 4 and Table 2).
Figure 5 summarizes the change in cytokine/growth factor
concentrations from baseline to immediate postexercise condi-
tions in both protocols. Changes from baseline to postexercise
were larger after the marathon race than after the field test for
HGF (P  0.01) and VEGF-D (P  0.01), suggesting a dose-
response relationship between endurance and maximal exercise
and release of these growth factors.
DISCUSSION
This study shows that, in trained amateur runners, release of
bone marrow-derived progenitors differed between a marathon
race and a maximal field test over 1,500 m. The data extend our
previous findings in amateur runners (3) by showing that
postexercise CD34 cell counts likely result from a complex
response to prolonged endurance exercise (i.e., marathon),
characterized by decreased circulating hemopoietic progenitors
and increased mobilization of angiogenetic progenitors. The
response to the maximal field test was similar to the one found
in rowers after supramaximal exercise (22), since both hemo-
poietic and angiogenetic progenitors increased immediately
Fig. 3. Effects of a marathon race and of 1.5-km
field test on circulating angiogenetic progenitors.
A and B: the results of flow cytometric analysis
for CD133VE-Cadherin cells (A) and
CD34KDR (B) cells, respectively. C: the re-
sults of the clonogenetic assay for angiogenetic
cells. D: exercise-induced changes in endothelial
progenitors after the marathon race (shaded bars)
and after the 1.5-km field test (open bars), ex-
pressed as % change from baseline. See text for
methodological details. Significant difference
(P  0.05): *vs. rest; §vs. pre-race; #vs. rest and
post-race. **Significant difference in the response
to marathon and field test.
Table 2. Growth factors and mediators
Marathon Field Test
Pre-Race End Race Post-Race Pre-Race End Race
IL-6, pg/ml 0.79 0.51 14.74 2.35a 0.98  0.44 0.67  0.46 1.50  1.10e
HGF, pg/ml 501 118 760  143a 566  400 596 130 716  154e
VEGF-A, pg/ml 185 111 137  133 201  163 208 114 194  113
VEGF-C, ng/ml 6.4 1.9 9.4  3.5 11.2  5.0c 7.3  1.8 8.8  1.7e
VEGF-D, ng/ml 0.7 0.5 1.0  0.8 0.3  0.4 0.4  0.2 0.5  0.2
Ang-1, ng/ml 6.4 9.9 13.4 6.3c 9.0  5.6 6.4  1.9 7.1  1.6
Ang-2, ng/ml 2.5 1.2 5.4  2.2a 2.7  1.1 3.0  1.2 4.2  1.4e
Ang-1/Ang-2 2.15 2.53 2.57  0.83 3.23  0.99 2.34  1.4 1.81  0.57
SCF, pg/ml 754 120 943  141c 813  105 905 124 1023 157e
CK, IU 159 56 233  94 793  512d nd nd
LDH, IU 464 92 683  143b 527  117 nd nd
Values are means  SE. HGF, hepatocyte growth factor; Ang, angiopoietin; SCF, stem cell factor; CK, creatine kinase; LDH, lactic dehydrogenase; nd, not
determined. aEnd of marathon significantly different from pre-race and post-race (P  0.05, ANOVA). bEnd of marathon significantly different from pre-race
and post-race (P  0.05, Kruskal-Wallis test). cSignificantly different from pre-race (P  0.05, ANOVA). dSignificantly different from pre-race and end of
marathon (P  0.05, ANOVA). eSignificantly different from pre-1,500 m (paired t-test).
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after exercise. These changes were associated with a different
pattern of release of growth/angiogenetic factors, suggesting
that the time course of progenitor release is modulated by the
type of exercise.
As an explanation for our findings, we hypothesize that,
during the marathon race, hemopoietic progenitors may mi-
grate from blood to peripheral tissues, whereas in the hours
following the end of the race a normal number of peripheral
blood hemopoietic progenitors is rapidly restored through the
migration of progenitors from bone marrow to peripheral
blood. Conversely, acute intense exercise mobilized progeni-
tors from the bone marrow. Our study extends the data recently
reported by Adams and coworkers (2) by showing that the
decrease in circulating hemopoietic progenitors after a mara-
thon race is not a peculiar response of aged individuals but also
occurs in younger athletes (average age in our sample was 43
yr vs. 57 yr in Adams’ study). Another study on long-distance
runners examined athletes after a 246-km race (10) and docu-
mented a long-lasting release of EPCs after the race. In our
study, all changes in progenitors were short-lived and had
returned to baseline the day after the race. The extreme features
of Spartathlon compared with marathon probably account for
the difference in results between studies.
In addition to total CD34 progenitors, we measured the
changes in the number of different hemopoietic progenitor
types (BFU-E, CFU-GM, and CFU-GEMM) occurring after a
marathon race or a maximal field test, providing evidence that
the changes in the number of these hemopoietic populations
strictly reflected the changes observed in total CD34 cells.
Interestingly, similar changes in BFU-E numbers have been
observed in athletes participating in the ultra-marathon Spar-
tathlon (35).
A most interesting finding regards the behavior of different
subpopulations of angiogenetic progenitors. CD34KDR cells,
CD133VE-cadherin cells, and monocyte-derived CACs ap-
peared to be highly regulated in athletes, and their response
modulated by the type of exercise. Indeed, CD34KDR cells
increased similarly after the marathon and the field test. Con-
versely, release of CD133VE-cadherin cells was largest
after the field test, whereas release of CAC preferentially
occurred after the marathon. These findings suggest a highly
regulated and possibly redundant system preserving endothe-
lial function and capillarization in response to intense exercise
in normal subjects. Differently from our results, Adams and
coworkers (2) reported unchanged number of CD34KDR
cells after the marathon race, but the proportion of angioge-
netic progenitors out of total progenitor counts increased post-
race also in their study. The older age of their sample may at
least partly account for different results. The same group
recently reported an increase in both total CD34 cells and
CD34/KDR EPCs at the end of strenuous endurance exer-
cise (4 h of cycling) (21), a condition similar to that observed
by us after the marathon race. Overall, these studies suggest
that endurance exercise induces a preferential differentiation of
CD34 cells toward EPCs. Alternatively, it can be hypothe-
sized that EPCs are directly mobilized from the bone marrow
by defined stimuli triggered by exercise. As for the physiolog-
ical relevance of exercise-induced EPC mobilization on skel-
etal muscle, most studies have used models of limb ische-
mia, i.e., a likely different stimulus compared with exercise in
normal subjects. The available data do suggest that exercise-
induced mobilization of EPC is associated with transcription of
VEGF-A in muscle tissue (38) and likely promotes new
vessel formation. However, an additional role of EPC on
proliferation of skeletal muscle cells cannot be excluded as
suggested by some experimental data obtained in a limb
ischemia model (19).
Fig. 5. Exercise-induced changes in growth factors after the marathon race
(shaded) and after the 1.5-km field test (open), expressed as % change from
baseline. HGF, hepatocyte growth factor; VEGF, vascular endothelial growth
factor; SCF, stem cell factor. *Significant difference between changes ob-
served after the marathon and field test (P  0.05).
Fig. 4. Effects of a marathon race and of a 1.5-km field test on plasma
angiopoietin-1 (top) and angiopoietin-2 (middle) levels. The ratio between
angiopoietin-1 and -2 was unaffected by exercise (bottom). See text for
methodological details. Significant difference (P  0.05): *vs. rest; §vs.
pre-race; #vs. rest and post-race.
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Our study may also be interpreted as providing information
on the time course of progenitor release, with changes after the
field test mainly representing the early response to exercise,
whereas the changes after the marathon would indicate the
response to prolonged aerobic exercise.
Our protocol is hardly comparable to that used by Laufs and
coworkers (17), but the postexercise increase in CD34KDR
cells we observed is of the same order of magnitude as the one
reported by these authors after 30 min of running in young
healthy subjects.
Exercise-induced release of progenitors was associated with
release of growth factors, which may help to understand the
mechanisms involved in progenitor mobilization. A dose-re-
sponse effect, with higher plasma concentrations after the
marathon compared with the field test, was evident for IL-6,
HGF, and angiopoietins, whereas SCF increased similarly in
both protocols. Increased IL-6 after exercise has been repeat-
edly reported, also by our group, and suggests activation of
inflammatory mechanisms during intense exercise in a dose-
dependent fashion (3, 10). The increased SCF value suggests,
together with our previous report of release of Flt3-ligand after
exercise (3), a possible trophic effect of exercise on the bone
marrow. Interestingly, bone marrow adipocytes decreased and
osteoblasts increased in response to exercise training in mice
(20). Since bone marrow adipocytes have been shown to exert
negative effects on hematopoiesis (23), we speculate that a
decreased number of adipocytes in the bone marrow may be
one mechanism by which exercise exerts a trophic effect on
bone formation and hematopoiesis.
Plasma VEGF-A was unaffected by either exercise protocol.
Our data therefore agree with other reports of unchanged
plasma VEGF-A concentration after exercise in normal sub-
jects (2, 18, 28, 39), suggesting that peripheral blood does not
reflect the exercise-induced VEGF-A expression that occurs in
skeletal muscle (8). Instead, increased plasma VEGF-A con-
centration after exercise has been found in patients with ische-
mic vascular disease (1, 30, 34), heart failure (6), or chronic
obstructive pulmonary disease (24), confirming a pivotal role of
hypoxia in causing VEGF-A release in peripheral blood. A shift
toward anaerobic metabolism during exercise may also account
for the slight increase in VEGF-A previously found in our study
in rowers after all-out exercise (22).
Little is known about the effects of exercise on plasma
concentrations of VEGF-C and VEGF-D. Both growth factors,
initially described as mediators of lymphatic vessel develop-
ment, are believed to be involved in new capillary growth
under normal and pathological conditions (36). Exercise has
been rarely investigated as a modulator of lymphatic vessel
development, but a study in mice found minor effects of acute
exercise and no change in lymphatics after training (14). In our
study VEGF-D increased more after the marathon than after
the field test, but the changes observed after exercise were
small compared with the other growth factors investigated, in
line with previous experimental data.
Among the growth factors of potential interest, the HGF is a
potent angiogenetic mediator. We previously reported in-
creased HGF concentrations after supramaximal exercise in
rowers (22) and after endurance exercise in patients with
chronic obstructive pulmonary disease (24). The present study
extends previous data by showing a significant increase in HGF
in healthy athletes, irrespective of the type of exercise. More-
over, recent data suggest that HGF may also modulate lym-
phangiogenesis (5).
Angiopoietins are important physiological factors acting in
concert with other angiogenetic factors to regulate blood vessel
stability and permeability (7). The plasma level of Ang-1 and
Ang-2 measured in well trained runners at rest were in the
same range as measured in aged healthy controls (6). Both
Ang-1 and Ang-2 increased after exercise, but their ratio
remained stable after exercise in both protocols. Elevated
plasma Ang-2 concentration has been found in critically ill
patients (15) and in advanced chronic obstructive pulmonary
disease patients (11), in agreement with its involvement in
inflammation. The stability of the Ang-1-to-Ang-2 ratio sug-
gests that intense exercise is not a significant pro-inflammatory
stimulus for endothelial cells in trained normal subjects.
Our study shows some limitations. First, due to the field type
of studies, only a small number of subjects could be included,
preventing correlation analysis between progenitor cell counts
and growth factor concentrations. Second, measurements of
progenitor cells in peripheral blood can only provide indirect
information on the bone marrow. Ethical reasons do not allow
bone marrow samples to be obtained from healthy subjects.
Finally, our results were obtained in a selected population of
well trained amateur athletes.
In conclusion, our study in healthy runners shows a complex
modulation of progenitor and mediator release after exercise,
with different patterns observed after endurance or maximal
exercise. Maximal exercise is associated with release of both
hemopoietic and endothelial progenitors, whereas high num-
bers of circulating endothelial progenitors are found after
prolonged endurance exercise together with reduced hemopoi-
etic progenitor counts. These findings suggest peripheral utili-
zation of bone marrow-derived cells during strenuous endur-
ance exercise. The different pattern of release of endothelial
progenitors during prolonged and short-lived maximal exercise
suggests very efficient and redundant angiogenetic mecha-
nisms operating in healthy endurance-trained subjects.
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